BeiGene will highlight data from arm D of the P-III (SEQUOIA) study of Brukinsa + venetoclax among treatment-naïve high-risk CLL/SLL patients at EHA 2024
The P-III (SEQUOIA) study for TN CLL/SLL has 3 cohorts, cohort 1 (n=479) for Brukinsa vs bendamustine + rituximab in patients without del(17p), cohort 2 (n=110) for Brukinsa alone in patients with del(17p) & cohort 3/arm D for Brukinsa + venetoclax in patients with del(17p) and/or TP53 mutation (n=66) & patients without del(17p) (n=48) were added later
The study, in 65 evaluable patients from arm D, showed 100% ORR, 48% CR+CRi rate (CR=46%; CRi=2%) & undetectable MRD in 59% at a median follow-up of 31.6mos. with mPFS not attained and PFS of 95% (12mos.) & 94% (24mos.)
Ref: BeiGene | Image: BeiGene
Related News:- GenFleet Partners with BeiGene to Conduct P-Ib/II Trial of GFH009 and Brukinsa for the Treatment of Diffuse Large B Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
